Cargando…
High numbers of CD163+ tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens
The prognostic significance of tumor-associated macrophages (TAMs) in multiple myeloma (MM) in the era of novel drugs remains unclear. CD163 expression was detected by immunohistochemistry to determine the number of TAMs in 198 MM patients receiving bortezomib-based regimens and the data were used t...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603386/ https://www.ncbi.nlm.nih.gov/pubmed/31289595 http://dx.doi.org/10.7150/jca.30102 |
_version_ | 1783431506538004480 |
---|---|
author | Wang, Hua Hu, Wan-ming Xia, Zhong-jun Liang, Yang Lu, Yue Lin, Shu-xia Tang, Hailin |
author_facet | Wang, Hua Hu, Wan-ming Xia, Zhong-jun Liang, Yang Lu, Yue Lin, Shu-xia Tang, Hailin |
author_sort | Wang, Hua |
collection | PubMed |
description | The prognostic significance of tumor-associated macrophages (TAMs) in multiple myeloma (MM) in the era of novel drugs remains unclear. CD163 expression was detected by immunohistochemistry to determine the number of TAMs in 198 MM patients receiving bortezomib-based regimens and the data were used to evaluate its relevance with clinical characteristics, treatment response, and prognosis. Patients with high levels of infiltrated CD163+ TAMs (>55/HPF) at diagnosis tended to have more adverse clinical characteristics. Patients with high CD163+ TAM content (>55/HPF) at diagnosis had worse progression-free survival (PFS) (P<0.001) and overall survival (OS) (P<0.001),and achieved lower complete remission (CR)/near-CR rate (P<0.001), than patients with low CD163+ TAM levels. Multivariate analysis revealed that CD163+ TAM content was an independent adverse prognostic factor for PFS and OS. Our data indicated that CD163+ TAM content at diagnosis is a powerful predictor of prognosis for MM in the era of novel drugs, and this discovery offers new insight into potential therapeutic strategies. |
format | Online Article Text |
id | pubmed-6603386 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-66033862019-07-09 High numbers of CD163+ tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens Wang, Hua Hu, Wan-ming Xia, Zhong-jun Liang, Yang Lu, Yue Lin, Shu-xia Tang, Hailin J Cancer Research Paper The prognostic significance of tumor-associated macrophages (TAMs) in multiple myeloma (MM) in the era of novel drugs remains unclear. CD163 expression was detected by immunohistochemistry to determine the number of TAMs in 198 MM patients receiving bortezomib-based regimens and the data were used to evaluate its relevance with clinical characteristics, treatment response, and prognosis. Patients with high levels of infiltrated CD163+ TAMs (>55/HPF) at diagnosis tended to have more adverse clinical characteristics. Patients with high CD163+ TAM content (>55/HPF) at diagnosis had worse progression-free survival (PFS) (P<0.001) and overall survival (OS) (P<0.001),and achieved lower complete remission (CR)/near-CR rate (P<0.001), than patients with low CD163+ TAM levels. Multivariate analysis revealed that CD163+ TAM content was an independent adverse prognostic factor for PFS and OS. Our data indicated that CD163+ TAM content at diagnosis is a powerful predictor of prognosis for MM in the era of novel drugs, and this discovery offers new insight into potential therapeutic strategies. Ivyspring International Publisher 2019-06-02 /pmc/articles/PMC6603386/ /pubmed/31289595 http://dx.doi.org/10.7150/jca.30102 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Wang, Hua Hu, Wan-ming Xia, Zhong-jun Liang, Yang Lu, Yue Lin, Shu-xia Tang, Hailin High numbers of CD163+ tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens |
title | High numbers of CD163+ tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens |
title_full | High numbers of CD163+ tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens |
title_fullStr | High numbers of CD163+ tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens |
title_full_unstemmed | High numbers of CD163+ tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens |
title_short | High numbers of CD163+ tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens |
title_sort | high numbers of cd163+ tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603386/ https://www.ncbi.nlm.nih.gov/pubmed/31289595 http://dx.doi.org/10.7150/jca.30102 |
work_keys_str_mv | AT wanghua highnumbersofcd163tumorassociatedmacrophagescorrelatewithpoorprognosisinmultiplemyelomapatientsreceivingbortezomibbasedregimens AT huwanming highnumbersofcd163tumorassociatedmacrophagescorrelatewithpoorprognosisinmultiplemyelomapatientsreceivingbortezomibbasedregimens AT xiazhongjun highnumbersofcd163tumorassociatedmacrophagescorrelatewithpoorprognosisinmultiplemyelomapatientsreceivingbortezomibbasedregimens AT liangyang highnumbersofcd163tumorassociatedmacrophagescorrelatewithpoorprognosisinmultiplemyelomapatientsreceivingbortezomibbasedregimens AT luyue highnumbersofcd163tumorassociatedmacrophagescorrelatewithpoorprognosisinmultiplemyelomapatientsreceivingbortezomibbasedregimens AT linshuxia highnumbersofcd163tumorassociatedmacrophagescorrelatewithpoorprognosisinmultiplemyelomapatientsreceivingbortezomibbasedregimens AT tanghailin highnumbersofcd163tumorassociatedmacrophagescorrelatewithpoorprognosisinmultiplemyelomapatientsreceivingbortezomibbasedregimens |